Interview Details - Overview

Upon completion of this educational activity, you should be able to:

• Assess current clinical data on emerging targeted therapies for patients with metastatic CRPC
• Incorporate newly approved chemotherapy for appropriate patients with metastatic CRPC following docetaxel failure
• Evaluate the safety and efficacy of RANKL-targeted therapy for patients with CRPC and bone metastases

Overview and Purpose

Overview and Purpose
Metastatic castration-resistant prostate cancer (CRPC) is a major health problem that accounts for nearly 1 in 10 cancer-related deaths in men in the United States. Until very recently, limited treatment options were available that improved survival for these patients. This has now changed with the approval of a new immunotherapy for asymptomatic/minimally symptomatic patients and a new cytotoxic agent for patients previously treated with standard first-line therapy. Novel androgen-targeted agents and other agents or combinations targeting the tumor microenvironment are showing promise in late-stage clinical trials. However, bone metastases and the associated morbidity remain a major concern in these patients, with a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor recently yielding a significant delay in the incidence of skeletal-related events compared with standard therapy.

The purpose of this activity is to inform physicians of recent advances in the treatment of patients with metastatic CRPC.

Target Audience
This educational activity is intended for medical oncologists involved in the care of patients with advanced CRPC. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.